FULC — Fulcrum Therapeutics Share News
0.000.00%
Last trade - 00:00- $253.21m
- -$80.11m
Brief: Fulcrum Therapeutics Sanofi To Terminate Collaboration And License Agreement With Fulcrum
Fulcrum Therapeutics Inc reports results for the quarter - Earnings Summary
Brief: Fulcrum Therapeutics Announces Recent Business Highlights And Financial Results For Q3 2024
Brief: Fulcrum Therapeutics Q3 Basic EPS USD -0.35
Fulcrum Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say (updated)
U.S. STOCKS ON THE MOVE-Starbucks, Crocs, Accenture
U.S. STOCKS ON THE MOVE-Crocs, First Solar, Qualcomm
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Sickle cell drug developers rise after Pfizer withdraws its treatment
Brief: Fulcrum Therapeutics Says It Plans To Reduce Workforce
Brief: TCG Crossover GP II Reports 9.4% Passive Stake In Fulcrum Therapeutics As Of Sept 12 - SEC Filing
U.S. RESEARCH ROUNDUP- Constellation Energy, Eli Lilly, Talen Energy
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Fulcrum Therapeutics tanks as muscle disorder drug fails in late-stage study
U.S. STOCKS ON THE MOVE-Fulcrum Therapeutics, Summit Therapeutics, Signet Jewelers
Fulcrum Therapeutics tanks as muscle disorder drug fails in late-stage study
Fulcrum stock slumps after muscle disorder drug fails in late-stage study (updated)